Prescribe Acthar Gel now
Start the referral process for your appropriate patients
Nelson WW, Lima AF, Kranyak J, Opong-Owusu B, Ciepielewska G, Gallagher JR, Heap K, Carroll S—Journal of Ocular Pharmacology and Therapeutics, 2019
Disclosure statement: Funding to support this study was provided by Mallinckrodt Pharmaceuticals.
To describe patient characteristics, utilization patterns of Acthar Gel and concomitant therapies, and physicians' assessments of Acthar Gel treatment effects on patients' health status
Patient population
Baseline patient and disease characteristics (N=91)
SD=standard deviation.
*Among 71 patients with documented prednisone treatment.
Baseline visual impairment level, n (%)
No patients were considered blind according to World Health Organization and ICD-10 criteria.
Uveitis symptoms and severity before initiation of Acthar Gel (N=91)
Available options included all those shown in the table. Respondents could select all options that applied; sum exceeds 100%.
Clinical outcomes may not be solely attributable to Acthar Gel.
Patient status remained the same: 16% (n=15)
OCT=optimal coherence tomography.
*Based on physicians' responses to the following two prompts:
Patient status remained the same: 16% (n=15)
Co-medication use in patients with uveitis 3 months
before, during,
and 3 months after treatment
with Acthar Gel1
Clinical outcomes may not be solely attributable to Acthar Gel.
Start the referral process for your appropriate patients
See additional dosing information from clinical experience with Acthar Gel
Download and fill out the Doctor Notification Letter to share your patient's prescription with their other healthcare providers.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: